olfactory receptor family 7 subfamily E member 106 pseudogeneGenealiases: OR14-NP2 · OR7E34P · OR7E40P · OST011 · OST215
Q-omics provides the consensus-scored OR7E106P profile across patient tissues and cancer cell-line models. OR7E106P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR7E106P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, OR7E106P RNA expression shows 7,256 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUSC, and THYM as cancer lineages where OR7E106P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E106P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E106P survival associations across molecular data types. OR7E106P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E106P RNA expression–survival associations across cancer types. High OR7E106P expression shows unfavorable associations in ACC, SKCM, UCS and DLBC, but favorable associations in HNSC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR7E106P RNA expression.
This table summarizes OR7E106P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E106P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E106P shows lower tumor expression in BRCA and higher tumor expression in LUSC. The LUSC box plot shows higher OR7E106P RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .008).
This table shows molecular features associated with OR7E106P in patient tissues and cancer cell lines. In patient samples, OR7E106P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
